Iveco Group N.V.
7.2.2025 07:30:00 CET | Globenewswire | Press release
Iveco Group 2024 Full Year and Fourth Quarter Results
Iveco Group 2024 Full Year and Fourth Quarter Results
The following is an extract from the “Iveco Group 2024 Full Year and Fourth Quarter Results (*). The complete press release can be accessed by visiting the media section of the Iveco Group corporate website: https://www.ivecogroup.com/media/corporate_press_releases or consulting the accompanying PDF:
The Board of Directors approves FY 2024 preliminary results, which mark another year of solid performance, and recommends an annual cash dividend of €0.33 per common share
The Board is considering separating the Defence business during 2025
through a spin-off
Consolidated revenues amounted to €15,289 million compared to €15,978 million in 2023. Net revenues of Industrial Activities were €14,948 million compared to €15,640 million in 2023, with positive price realisation partially offsetting lower volumes in Truck and Powertrain.
Adjusted EBIT was €982 million (€11 million increase compared to 2023) with a 6.4% margin (up 30 bps compared to 2023). Adjusted EBIT of Industrial Activities was €851 million (€849 million in 2023), with positive price realisation more than offsetting lower volumes. Adjusted EBIT margin of Industrial Activities was 5.7% (up 30 bps compared to 2023), with margin improvements in Bus, Defence and Powertrain.
Adjusted net income was €569 million (up €181 million compared to 2023) after excluding from the €394 million reported net income, primarily the loss of €145 million from the transfer of the Fire Fighting business, €96 million in engine campaign costs, and a €94 million tax benefit due to the recognition of deferred tax assets in the German jurisdiction. Adjusted diluted earnings per share was €2.09, up €0.74 compared to 2023.
Net financial expenses amounted to €211 million (€443 million in 2023), an improvement of €232 million compared to 2023 mainly due to a more contained cost of hedge impact in Argentina, resulting from the implemented hedging strategy, and an improvement in the Argentinian hyperinflation accounting impact.
Reported income tax expense was €69 million, with an adjusted Effective Tax Rate (adjusted ETR) of 26% in 2024. The adjusted ETR reflects the different tax rates applied in the jurisdictions where the Group operates and some other discrete items.
Free cash flow of Industrial Activities was positive at €402 million (€450 million in 2023) as a result of an optimised management of production levels to adapt to a lower industry demand, and an effective hedging strategy to reduce the Argentinian foreign exchange exposure.
Available liquidity was €5,474 million as of 31st December 2024, up €726 million from 31st December 2023, including €1,900 million of undrawn committed facilities.
(*) 2024 financial data shown refers to Continuing Operations only, unless otherwise stated. Continuing Operations exclude the Fire Fighting business which, following the signing of a definitive agreement for the transfer of its ownership, has been classified as Discontinued Operations; the transfer was completed on 3rd January 2025. 2023 comparative figures have been recast consistently.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S13.6.2026 18:45:00 CEST | Press release
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
King Faisal Specialist Hospital & Research Centre13.6.2026 15:57:00 CEST | Press release
KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026
Chery Group13.6.2026 11:39:45 CEST | Press release
FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch
Hotel Belles Rives13.6.2026 00:11:17 CEST | Press release
Julian Barnes Named Laureate of the 2026 Fitzgerald Prize
Sanofi Winthrop Industrie13.6.2026 00:09:43 CEST | Press release
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom